Hexahydro[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine deuterated derivative, pharmaceutical composition thereof, preparation method therefor, and Anti-influenza use thereof

Cap dependence is inhibited by the development of hexahydro[1,4]oxazine[3,4-C]pyridino[2,1-F][1,2,4]triazine deuterated derivatives and pharmaceutical compositions thereof The endonuclease of nucleic acid PA enzyme solves the problem of poor resistance and inhibition of existing anti-influenza drugs, and achieves effective inhibition and treatment of influenza viruses.

WO2024234474A1PCT designated stage expired Publication Date: 2024-11-21CHANGSHA JINGYI PHARM TECH CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/107754
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2023-07-17
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing anti-influenza drugs are prone to influenza virus resistance and are difficult to effectively inhibit cap-dependent endonuclease, resulting in poor efficacy in treating influenza.

Method used

A deuterated derivative of hexahydro[1,4]oxazine[3,4-C]pyridino[2,1-F][1,2,4]triazine and its pharmaceutical composition were developed by Inhibit cap-dependent endonuclease, blocks the transcription process of influenza viruses, and is used to treat influenza. The compound can be administered in a variety of dosage forms, including oral, topical administration, etc., to prevent, treat or alleviate influenza virus infection.

Benefits of technology

The compound showed better pharmacological activity and drug properties, could effectively inhibit the replication of influenza A and B viruses, significantly relieve symptoms, and showed excellent anti-influenza effects in vivo and in vitro, and had better safety and pharmacokinetic characteristics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023107754_21112024_PF_FP_ABST
    Figure CN2023107754_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present application provides a novel compound and a preparation method therefor. The compound specifically relates to a cap-dependent nucleic acid PA endonuclease inhibitor and intermediates for preparation of the compound. Further provided are a pharmaceutical composition of the compound, and a use of the compound and the pharmaceutical composition of the compound in treating influenza. The compound is suitable for being prepared into drugs of various dosage forms, and can be widely used for treating seasonal influenza.
Need to check novelty before this filing date? Find Prior Art

Description

Hexahydro[1,4]oxazino[3,4-C]pyrido[2,1-F][1,2,4]triazine deuterated derivative, pharmaceutical composition, preparation method and use thereof in treating influenza Technical Field

[0001] The present application belongs to the field of medicine, and specifically relates to a compound and a preparation method thereof, a pharmaceutical composition of the compound, and the use of the compound and the pharmaceutical composition of the compound in treating influenza. Background Art

[0002] Once the influenza virus enters the host cell, its replication and transcription in the host cell are inseparable from the catalysis of RNA polymerase. Among them, the cap-dependent nuclease PA endonuclease is an enzyme necessary for the synthesis of viral mRNA. By inhibiting the cap-dependent nuclease PA endonuclease, the transcription process of the influenza virus can be selectively blocked, thereby achieving the purpose of preventing, treating or alleviating influenza in patients.

[0003] Currently, commonly used anti-influenza drugs include: ion channel M2 inhibitors, such as amantadine and methylamantadine; neuraminidase inhibitors, such as oseltamivir, zanamivir, and peramivir; and other drugs, such as morphine and ribavirin. However, influenza viruses are prone to mutation and have developed resistance to currently used anti-influenza drugs, necessitating the continued development of new anti-influenza drugs.

[0004] Deuterium (D), also known as heavy hydrogen, is a non-radioactive isotope of hydrogen. Modifying drugs with deuterium can improve their absorption, distribution, metabolism, and / or excretion (ADME) properties while retaining the original drug's biological activity. Therefore, research on deuterated anti-influenza drugs is a way to expand the selection of anti-influenza drugs.

[0005] Summary of the Invention

[0006] The present application provides a compound and a preparation method thereof, a pharmaceutical composition of the compound, and uses of the compound and the pharmaceutical composition of the compound in treating influenza.

[0007] In one aspect, the present application provides a compound, which is a compound represented by Formula X or a pharmaceutically acceptable salt thereof,

[0008] wherein R is selected from H, Fmoc or

[0009] On the other hand, the present application provides a pharmaceutical composition comprising an effective amount of a compound of formula X or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein R is

[0010] The pharmaceutically acceptable excipients include solvents, diluents, other liquid excipients, dispersants or suspending agents, surfactants, isotonic agents, thickeners, emulsifiers, preservatives, solid binders or lubricants, etc.

[0011] In some embodiments, the pharmaceutical composition comprises one or more additional therapeutic agents.

[0012] In some embodiments, the additional therapeutic agent is selected from an anti-influenza virus agent or a vaccine.

[0013] In some embodiments, the other therapeutic agent is selected from at least one of oseltamivir, zanamivir, peramivir, laninamivir, favipiravir, arbidol hydrochloride, amantadine, methylamantadine, ribavirin, stavroprine, ingavirine, baloxavir, and vaccines.

[0014] In some embodiments, the pharmaceutical composition can be in liquid, solid, semisolid, gel or spray form.

[0015] The compounds or pharmaceutically acceptable compositions of the present application can be administered by any suitable means, and can be administered to humans or other animals orally, rectally, parenterally, intracisternal, intravaginal, intraperitoneally or topically, depending on the severity of the disease. The preferred method is oral administration.

[0016] The compounds of the present application or their pharmaceutical compositions may be administered in a unit dosage form. The dosage form may be a liquid or solid dosage form. Liquid dosage forms may include solutions, colloids, microparticles, or suspensions; other dosage forms include tablets, capsules, pellets, aerosols, pills, powders, emulsions, granules, suppositories, lyophilized powder injections, inclusion compounds, implants, patches, and liniments.

[0017] Tablets and capsules for oral administration may contain excipients such as binders such as syrup, gum arabic, sorbitol, tragacanth, or polyvinyl pyrrolidone; fillers such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants such as magnesium stearate, talc, polyethylene glycol, or silica; disintegrants such as potato starch; or an acceptable wetting agent such as sodium lauryl sulfate. Tablets may be coated by methods known in the pharmaceutical industry.

[0018] Oral solutions can be prepared as suspensions, solutions, emulsions, syrups, or elixirs of hydrated oils, or as dry products, to be reconstituted with water or other suitable media before use. Oral solutions may contain conventional additives, such as suspending agents such as sorbitol, methyl cellulose, or glucose syrup; emulsifiers such as lecithin, sorbitan monooleate, or gum arabic; or non-aqueous excipients (which may include edible oils such as almond oil or fats such as glycerol, ethylene glycol, or ethanol); and preservatives such as methyl parahydroxybenzoate, propyl parahydroxybenzoate, or sorbic acid. Flavoring or coloring agents may be added as needed.

[0019] Suppositories may contain conventional suppository bases such as cocoa butter or other glycerides.

[0020] For parenteral administration, liquid dosage forms are typically prepared from the compound and a sterile excipient. The preferred excipient is water. Depending on the excipient and drug concentration, the compound can be dissolved in the excipient or prepared as a suspension. For injectable solutions, the compound is first dissolved in water, filtered, sterilized, and then filled into a sealed bottle or ampoule.

[0021] When applied topically to the skin, the compounds of the present application can be formulated into suitable ointments, lotions or creams, wherein the active ingredient is suspended or dissolved in one or more excipients, wherein the excipients that can be used in ointment preparations include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyethylene oxide, polypropylene oxide, emulsifying wax and water; and the excipients that can be used in lotions and creams include, but are not limited to, mineral oil, sorbitan monostearate (Tween 60), cetyl esters wax, hexadecene alcohol, 2-octyldodecanol, benzyl alcohol and water.

[0022] On the other hand, the present application provides the use of a compound of formula X and a pharmaceutical composition of a compound of formula X in the preparation of a drug for preventing, treating, curing or alleviating influenza virus infection in a patient, wherein R is

[0023] In some embodiments, the influenza virus infection is an influenza A virus infection or an influenza B virus infection.

[0024] On the other hand, the present application provides a compound of formula X and a pharmaceutical composition of a compound of formula X for use in preparing a drug for preventing, treating, curing or alleviating influenza virus infection in a patient, wherein R is

[0025] In some embodiments, the influenza virus infection is an influenza A virus infection or an influenza B virus infection.

[0026] On the other hand, the present application provides a method for preventing, treating, curing or alleviating influenza virus infection in a patient, which comprises administering a pharmaceutically acceptable effective dose of the compound or pharmaceutical composition of the present application to the patient.

[0027] Preferably, the influenza virus infection is influenza A virus infection or influenza B virus infection.

[0028] The present application provides a method for preventing, treating, or alleviating an infection caused by influenza virus, comprising administering a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable composition thereof to a patient in need of treatment. Furthermore, the pharmaceutical composition may be administered together with one or more other therapeutic agents.

[0029] On the other hand, the present application provides the use of a compound of formula X and a pharmaceutical composition of a compound of formula X in the preparation of a drug for inhibiting RNA polymerase of influenza virus, wherein R is

[0030] Preferably, the RNA polymerase is a cap-dependent PA endonuclease.

[0031] Unless otherwise indicated, the present application includes stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, and pharmaceutically acceptable salts of the compounds of the present application. The term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients in the formulation and the mammals to be treated therewith.

[0032] On the other hand, the present application provides an intermediate for preparing a compound of formula X, wherein the intermediate has the structure of the following compound of formula III:

[0033] In some embodiments, the present application also provides a method for preparing a compound of formula III, comprising condensing compound II, 9-fluorenylmethyl chloroformate, a base, and a reaction solvent at a certain temperature, and then hydrolyzing the compound in the presence of a catalyst and an organic solvent to produce the compound of formula III.

[0034] In some embodiments, the reaction solvent of the condensation reaction is selected from at least one of 1,4-dioxane, tetrahydrofuran, or acetonitrile. In some embodiments, the reaction solvent is 1,4-dioxane, which is beneficial to the reaction and post-processing.

[0035] In some embodiments, the reaction temperature of the condensation reaction is 0-40° C. In some embodiments, the condensation reaction temperature is 25° C., which is conducive to the reaction.

[0036] In some embodiments, the base of the condensation reaction is selected from sodium bicarbonate solution and / or sodium carbonate solution. In some embodiments, the base is sodium bicarbonate solution, which is conducive to the reaction and post-processing.

[0037] In some embodiments, the molar ratio of the compound II to 9-fluorenylmethyl chloroformate is 1:1-3. In some embodiments, the molar ratio of the compound II to 9-fluorenylmethyl chloroformate is 1:1, which is beneficial to the formation and acquisition of the product.

[0038] In some embodiments, the molar ratio of the compound II to the base is 1:1-3. In some embodiments, the molar ratio of the compound II to the base is 2:3, which is beneficial to the formation and acquisition of the product.

[0039] In some embodiments, the reaction temperature of the hydrolysis reaction is 60-100° C. In some embodiments, the reaction temperature of the hydrolysis reaction is 80° C., which is conducive to the reaction.

[0040] In some embodiments, the reaction solvent of the hydrolysis reaction is selected from N-methylpyrrolidone and / or N,N-dimethylformamide. In some embodiments, the reaction solvent is N-methylpyrrolidone, which is conducive to the reaction and post-processing.

[0041] In some embodiments, the catalyst for the hydrolysis reaction is lithium chloride, which is beneficial to the formation and acquisition of the product.

[0042] In some embodiments, the molar ratio of the compound II to the catalyst is 1:6-12. In some embodiments, the molar ratio of the compound II to the catalyst is 1:9, which is beneficial to the formation and acquisition of the product.

[0043] After the reaction is complete, post-treatment is optionally performed. In some embodiments, the post-treatment comprises: after the reaction is complete, cooling the resulting mixed solution, adding water for crystallization, and filtering to obtain an off-white solid Compound III.

[0044] On the other hand, the present application provides a method for preparing a compound of formula X, wherein R is Fmoc. When R is Fmoc, the structure of the compound of formula X is as shown in the compound of formula VII:

[0045] The preparation method comprises the following steps:

[0046] Step 1: Compound IV, compound V, an acid-binding agent, and a reaction solvent undergo an esterification reaction at a certain temperature to produce a compound of formula VI;

[0047] Step 2: Compound III, compound VI, a base, a catalyst, and a reaction solvent undergo a substitution reaction at a certain temperature to produce a compound of formula VII;

[0048] In step 1, the reaction solvent is selected from at least one of dichloromethane, anhydrous ether or tetrahydrofuran. In some embodiments, the reaction solvent is dichloromethane, which is conducive to the reaction and post-processing.

[0049] In step 1, the reaction temperature is -10-40° C. In some embodiments, the reaction temperature is 0-30° C., which is conducive to the reaction.

[0050] In step 1, the acid binding agent is selected from pyridine and / or triethylamine. In some embodiments, the acid binding agent is pyridine, which is conducive to the formation and acquisition of the product.

[0051] In step 1, the molar ratio of compound IV to compound V is 1:0.8-1.5. In some embodiments, the molar ratio of compound IV to compound V is 1:1, which is conducive to the formation and acquisition of the product.

[0052] In step 1, the molar ratio of compound IV to the acid-binding agent is 1:1-2. In some embodiments, the molar ratio of compound IV to the acid-binding agent is 1:1.2, which is conducive to the formation and acquisition of the product.

[0053] In step 1, after the reaction is complete, post-treatment is optionally performed. In some embodiments, the post-treatment comprises: quenching the reaction solution after the reaction is complete, allowing the quenched reaction solution to stand for separation, washing the organic phase with saturated brine, drying over anhydrous sodium sulfate, and concentrating to obtain compound VI.

[0054] In step 2, the reaction solvent is selected from at least one of N,N-dimethylformamide, N,N-dimethylacetamide or acetone. In some embodiments, the reaction solvent is N,N-dimethylformamide, which is conducive to the reaction and post-processing.

[0055] In step 2, the reaction temperature is 40-70° C. In some embodiments, the reaction temperature is 60° C., which is conducive to the reaction.

[0056] In step 2, the base is selected from at least one of potassium carbonate, cesium carbonate, potassium phosphate or sodium carbonate. In some embodiments, the base is potassium carbonate, which is beneficial to the reaction and post-processing.

[0057] In step 2, the catalyst is selected from at least one of potassium iodide, sodium iodide, or potassium bromide. In some embodiments, the catalyst is potassium iodide, which is beneficial to the reaction and post-processing.

[0058] In step 2, the molar ratio of compound III to compound VI is 1:1-3. In some embodiments, the molar ratio of compound III to compound VI is 1:2, which is conducive to the formation and acquisition of the product.

[0059] In step 2, the molar ratio of the compound III to the base is 1:1-3. In some embodiments, the molar ratio of the compound III to the base is 1:2, which is conducive to the formation and acquisition of the product.

[0060] In step 2, the molar ratio of the compound III to the catalyst is 1:0.1-3. In some embodiments, the molar ratio of the compound III to the catalyst is 1:0.5, which is conducive to the formation and acquisition of the product.

[0061] In step 2, after the reaction is complete, post-treatment is optionally performed. In some embodiments, the post-treatment comprises: after the reaction is complete, cooling the resulting mixed solution, adding water for crystallization, filtering, and drying to obtain a light yellow solid Compound VII.

[0062] In another aspect, the present application provides a method for preparing a compound of formula X, wherein R is H. When R is H, the structure of the compound of formula X is as shown in formula VIII:

[0063] The preparation method comprises the steps of: performing a deprotection reaction of compound VII, a base, and an organic solvent at a certain temperature to generate a compound of formula VIII;

[0064] In some embodiments, the reaction solvent is dichloromethane, which is beneficial to the reaction and post-processing.

[0065] In some embodiments, the reaction temperature is 10-40° C. In some embodiments, the reaction temperature is 20° C., which is conducive to the reaction.

[0066] In some embodiments, the base is selected from at least one of hexahydropyridine, concentrated aqueous ammonia, piperidine, or 1,8-diazabicyclo[5.4.0]undec-7-ene. In some embodiments, the base is hexahydropyridine, which is beneficial to the formation and acquisition of the product.

[0067] In some embodiments, the molar ratio of the compound VII to the base is 1:0.5-3. In some embodiments, the molar ratio of the compound VII to the base is 1:1, which is beneficial to the formation and acquisition of the product.

[0068] After the reaction is complete, post-treatment is optionally performed. In some embodiments, the post-treatment comprises: adding a solvent to the solid mixture obtained after the reaction is complete, recrystallizing, filtering, and drying to obtain a white solid compound VIII.

[0069] On the other hand, the present application provides a method for preparing a compound of formula X, wherein R is When R is When the structure of the compound of formula X is as shown in the compound of formula I, the preparation method comprises the steps of condensing compound VIII, compound IX, a condensing agent, a catalyst, and an organic solvent at a certain temperature to generate the compound of formula I;

[0070] In some embodiments, the reaction solvent is ethyl acetate and / or cyclohexane, which is beneficial to the reaction and post-processing.

[0071] In some embodiments, the reaction temperature is 60-80° C. In some embodiments, the reaction temperature is 70° C., which is conducive to the reaction.

[0072] In some embodiments, the condensing agent is selected from at least one of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-propyl phosphoric anhydride, or N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate. In some embodiments, the catalyst is 1-propyl phosphoric anhydride, which is beneficial for the formation and acquisition of the product.

[0073] In some embodiments, the catalyst is methanesulfonic acid, which is beneficial to the formation and acquisition of the product.

[0074] In some embodiments, the molar ratio of compound VIII to compound IX is 1:1-3. In some embodiments, the molar ratio of compound VIII to compound IX is 1:1.2, which is beneficial for the formation and acquisition of the product.

[0075] In some embodiments, the molar ratio of the compound VIII to the condensing agent is 1:1-4. In some embodiments, the molar ratio of the compound VIII to the condensing agent is 1:1.5, which is conducive to the formation and acquisition of the product.

[0076] In some embodiments, the molar ratio of the compound VIII to the catalyst is 1:0.5-4. In some embodiments, the molar ratio of the compound VIII to the catalyst is 1:2.5, which is beneficial for the formation and acquisition of the product.

[0077] After the reaction is complete, post-treatment is optionally performed. In some embodiments, the post-treatment comprises: after the reaction is complete, cooling the resulting mixed solution, extracting, drying, recrystallizing, filtering, and drying to obtain Compound I as an off-white solid.

[0078] On the other hand, the present application provides a method for preparing a compound of formula X, wherein R is The preparation method comprises the following steps:

[0079] Step 1: Compound II, 9-fluorenylmethyl chloroformate, sodium bicarbonate, and 1,4-dioxane are subjected to a condensation reaction at 0-40°C, followed by a hydrolysis reaction with lithium chloride and N-methylpyrrolidone at 60-100°C to produce a compound of formula III;

[0080] Step 2: Compound IV, compound V, pyridine, and dichloromethane undergo esterification reaction at -10-40°C to produce compound VI; Compound III, compound VI, potassium carbonate, potassium iodide, and N,N-dimethylformamide undergo substitution reaction at 40-70°C to produce compound VII;

[0081] Step 3: Compound VII, hexahydropyridine, and dichloromethane undergo a deprotection reaction at 10-40° C. to produce a compound of formula VIII; and

[0082] Step 4: Compound VIII, compound IX, 1-propylphosphoric acid cyclic anhydride, methanesulfonic acid, ethyl acetate, and cyclohexane undergo condensation reaction at 60-80° C. to produce a compound of formula I;

[0083] It will be understood that if there is any discrepancy between a chemical name and a chemical structure in this specification, the structure shall prevail.

[0084] Compared with existing similar compounds, the compound I of the present application has better pharmacological activity. Therefore, the compound I provided by the present application has better drugability than existing similar compounds.

[0085] In summary, the present application provides a compound and a method for preparing the same. Compound I specifically relates to a cap-dependent PA endonuclease inhibitor. Compounds III, VII, and VIII can all serve as intermediates for preparing Compound I. The present application also provides pharmaceutical compositions of Compound I, as well as the use of Compound I and pharmaceutical compositions of Compound I in treating influenza. The compound is suitable for preparation into a variety of dosage forms and can be widely used to treat seasonal influenza. BRIEF DESCRIPTION OF THE DRAWINGS

[0086] FIG1 is a hydrogen nuclear magnetic resonance spectrum of compound I prepared in Example 5 of the present application.

[0087] Figure 2 is a carbon NMR spectrum of compound I prepared in Example 5 of the present application.

[0088] Figure 3 is a mass spectrum of compound I prepared in Example 5 of the present application. DETAILED DESCRIPTION

[0089] Definitions and General Terms

[0090] The term "comprising" is an open expression, that is, including the contents specified in the application, but not excluding other contents.

[0091] The term "stereoisomer" includes enantiomers, diastereomers, conformers (rotamers), geometric isomers (cis / trans isomers), atropisomers, etc. Depending on the choice of starting materials and process, the compounds of the present invention may exist in the form of one of the possible isomers or a mixture thereof, such as a racemate and a diastereomeric mixture (depending on the number of asymmetric carbon atoms).

[0092] The term "pharmaceutically acceptable salts" refers to organic and inorganic salts of the compounds of the present application.

[0093] The compounds of the present invention, including their salts, may also be obtained in the form of their hydrates, or include other solvents for their crystallization. The compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, the present invention also includes their solvated and unsolvated forms.

[0094] The term "effective amount" refers to an amount of the compound of the present application that elicits a desired biological response. In the present application, the desired biological response is a reduction in the amount of influenza virus or a reduction or improvement in the severity, duration, progression, or onset of influenza virus infection; prevention of the spread of influenza virus infection; prevention of the recurrence, evolution, onset, or progression of symptoms associated with influenza virus infection; or enhancement or improvement of the prophylactic or therapeutic effect of another anti-influenza infection therapy being used.

[0095] The terms "first" and "second" are used for descriptive purposes only and should not be understood to indicate or imply relative importance or implicitly specify the number of the technical features indicated. Therefore, a feature specified as "first" or "second" may explicitly or implicitly include one or more of the features. In the description of this application, "plurality" means two or more, unless otherwise specifically defined.

[0096] The descriptions of the terms "one embodiment", "some embodiments", "examples", "specific examples", or "some examples" mean that the specific features, structures, materials, or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present application. In this specification, the schematic expressions of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials, or characteristics described can be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art can combine and combine different embodiments or examples described in this specification and features of different embodiments or examples without contradiction.

[0097] In this application, expressions such as "compound I", "compound represented by formula I" and "formula I" refer to the same compound.

[0098] In the present application, "optionally" or "optionally" means that it may or may not be present; or it may or may not be performed; for example, "optionally adding a reaction solvent to the crude product obtained in step one" means that a reaction solvent may or may not be added to the crude product obtained in step one.

[0099] In order to enable those skilled in the art to better understand the technical solution of the present application, some non-limiting embodiments are further disclosed below to further explain the present application in detail.

[0100] The reagents used in this application can be purchased from the market or prepared by the methods described in this application.

[0101] In the present application, the reaction is considered complete when the remaining amount of the raw materials does not exceed 5% or 3% or 2% or 1% or 0.5% of the amount of the raw materials charged.

[0102] In this application, the statistical P value range means that 0.01<P<0.05 indicates a significant difference, usually marked with ×; P<0.01 indicates an extremely significant difference, usually marked with ××.

[0103] The T-3 compound and T-4 compound used in this application were prepared according to the method described in patent CN 110317211A.

[0104] Preparation Example

[0105] Example 1 Preparation of (9H-fluoren-9-yl)methyl (R)-7-hydroxy-6,8-dioxo-1,3,4,6,8,12a-hexahydro-12H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-12-carboxylate (Compound III)

[0106] (R)-7-benzyloxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazine[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione (Compound II, 6.5 g, 20 mmol), 9-fluorenylmethyl chloroformate (5.6 g, 21 mmol), 1,4-dioxane (65.1 g), 10% sodium bicarbonate solution (25.2 g, 30 mmol), the reaction system was reacted at 25 ° C for 4 h, dichloromethane (195.7 g) was added to the reaction system for extraction three times, the organic phases were combined, purified water (125.8 g) was added and stirred and washed twice, the mixture was allowed to stand for separation, anhydrous sodium sulfate (22.6 g) was added to the organic phase, stirred and dried for 1 h, filtered, and the filtrate was spin-dried at 50 ° C, N-methylpyrrolidone (76.9 g) and lithium chloride (7.6 g, 180 mmol) were added, the mixture was stirred and heated to 80 ° C for 12 h, cooled to 10 ° C, purified water (210.7 g) was added dropwise to the reaction system, the temperature was cooled to 0-20 ° C for crystallization for 1 h, and 7.4 g of compound III was obtained by filtration (off-white solid, purity 95%, yield 81.0%).

[0107] 1 HNMR (CDCl3) δ: 10.10 (1H, s), 7.79 (2H, d), 7.62 (2H, m), 7.34~7.43 (4H, m), 6.96 (1H, d), 6.28 (1H, d), 5.57 (1H, m), 4.70 (2H, d), 4.46 (1H, d), 4.02 (1H, m), 3.77 (1H, m), 3.40~3.64 (4H, m).

[0108] Example 2 Preparation of Chloromethyl (Ethyl-d5) Carbonate (Compound VI)

[0109] Compound IV (5.0 g, 38.8 mmol) and pyridine (3.4 g, 43 mmol) were added to dichloromethane (125.7 g), and the temperature of the mixed solution was lowered to -5 ° C. Then, compound V (2.4 g, 46.1 mmol) was dissolved in dichloromethane (10.1 g) and slowly added dropwise to the above mixed solution. After the addition was complete, the reaction temperature was raised to 0 ° C and kept for 0.5 h, and then raised to 20 ° C and reacted for 2 h. After the reaction was complete, it was quenched with dilute hydrochloric acid (2 mol / L, 40 mL), allowed to stand and separated, and the organic phase was washed with saturated brine (40 mL * 2), dried over anhydrous sodium sulfate (22.6 g), filtered, and concentrated to obtain 5.0 g of compound VI (light yellow liquid, purity 97%, yield 90%).

[0110] Example 3 Preparation of (9H-fluoro-9-yl)methyl (R)-7-(ethoxy-d5)carbonyl)oxy)methoxy)-6,8-dioxo-1,3,4,6,8,12a-hexahydro-12H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-12-carboxylate (Compound VII)

[0111] Compound III (7.2 g, 15.7 mmol), compound VI (4.5 g, 31.3 mmol), potassium carbonate (4.4 g, 31.8 mmol) and potassium iodide (1.3 g, 7.8 mmol) were sequentially added to N,N-dimethylformamide (72.0 g) and mixed. The mixed solution was heated to 60°C and reacted for 12 h, then cooled to 0°C, and water (150 mL) was added for crystallization. The product was filtered and the solid was dried to obtain 7.5 g of solid compound VII (light yellow solid, purity 96% and yield 87%).

[0112] 1 HNMR (CDCl3) δ: 7.90 (2H, d), 7.65 (2H, m), 7.28~7.38 (4H, m), 6.99 (1H, d), 6.83 (2H, m), 6.33 (1H, d), 5.61 (1H, m), 4.75 (2H, d), 4.50 (1H, d), 4.05 (1H, m), 3.81 (1H, m), 3.45~3.66 (4H, m).

[0113] Example 4 Preparation of (R)-((6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl)oxy)methyl(ethyl-d5)carbonate (Compound VIII)

[0114] Compound VII (7.0 g, 12.7 mmol), hexahydropyridine (1.1 g, 12.9 mmol), and dichloromethane (186.2 g) were added to the reaction flask in sequence. The reaction system was stirred at 20°C for 2 h, then transferred to 50°C and dried by rotation. Methanol (126.1 g) was added to the reaction system for recrystallization, filtered, and dried under vacuum at 60°C to obtain 3.9 g of compound VIII (off-white solid, purity 98% and yield 90%).

[0115] 1 HNMR (CDCl3) δ: 6.97 (1H, d), 6.79 (2H, m), 6.41 (1H, m), 6.31 (1H, d), 5.57 (1H, m), 3.98 (1H, m), 3.73 (1H, m), 3.40~3.57 (4H, m).

[0116] Example 5 Preparation of [[(12aR)-12-[(11S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiocycloheptatrienyl-11-yl]-6,8-dioxo-3,4,6,8,12,12a-hexahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin-7-yl]oxy]methyl(ethyl ester-d5) carbonate (Compound I)

[0117] Ethyl acetate (12.8 g), cyclohexane (4.5 g), compound VIII (3.0 g, 8.7 mmol) and compound IX (2.8 g, 10.6 mmol) were added to the reaction flask in sequence. 1-propylphosphoric acid cyclic anhydride (50% ethyl acetate solution) (8.3 g, 13.0 mol) was added dropwise to the reaction system under stirring. Then, methanesulfonic acid (2.1 g, 21.8 mmol) was added dropwise to the reaction system. The reaction system was heated to 70°C for 24 h, then cooled to 20°C. 20% sodium hydroxide solution was added dropwise to the reaction system under stirring. The pH of the reaction system was adjusted to 7, and the mixture was allowed to stand for separation. The upper organic phase was taken, and the aqueous phase was extracted with ethyl acetate (30.0 g) under stirring. The mixture was allowed to stand for separation, and the upper organic phase was taken. The organic phases were combined, anhydrous sodium sulfate (22.6 g) was added to the organic phase and dried for 1 h, filtered, and the filtrate was transferred to 60°C and spin-dried to obtain a brown oil, which was dissolved in dichloromethane (24.1 g). n-Heptane (26.5 g) was added dropwise to the reaction system under stirring, and the temperature was lowered to 10°C and stirred for crystallization for 1 h. The mixture was filtered and the filter cake was transferred to 60°C and dried in vacuo to obtain 4.0 g of a solid, which was Compound I (off-white solid, purity 98%, yield 78%).

[0118] 1 HNMR(DMSO-d6)δ: 7.34~7.42(2H,m), 7.19(1H,dd), 7.15(1H,m), 7.13(1H,m), 7.07~7.11(1H,dd), 5.51~5.71(3H,m), 5.37~5.41(1H , dd), 4.35~4.44(2H,m), 3.95~4.05(2H,ddd), 3.64~3.68(1H,dd), 3.44~3.54(2H,m), 3.42(1H,t), 3.22~3.28(1H,m), 2.92(1H,m).

[0119] Activity test example

[0120] Example A In vitro anti-influenza virus pharmacodynamics experiment

[0121] This example studies the inhibitory effect of the compound of formula I on influenza A virus (H3N2) and influenza B virus (IBV) in vitro.

[0122] The in vitro cytotoxicity of the test compound of formula I and the positive control drugs maloxavir, baloxavir, T-3 compound, and T-4 compound on canine kidney cells (MDCK) was determined using Cell Counting Kit (CCK-8): MDCK cells were seeded in 96-well plates and cultured overnight, and different concentrations of drugs were added and incubated for 48 hours. CCK-8 was then added and incubated in the dark for 14 hours. The OD was measured on a microplate reader. 450nm The half-maximal inhibitory concentration (IC50) of the drug on cells was calculated.

[0123] The cytopathic effect assay (CPE) was used to determine the in vitro inhibitory effects of the test compound of formula I and the positive control drugs mabaloxavir, baloxavir, T-3 compound, and T-4 compound on influenza A virus subtype H3N2 strain (A / California / 2 / 2014) and influenza B virus strain (B / Florida / 78 / 2015): MDCK cells were seeded in 96-well plates and cultured overnight. 100 TCID 50 (Influenza A: 10 -0.13 / 0.1mL, B flow: 10 -0.29 / 0.1mL) virus was adsorbed for 2 hours to infect cells, and then culture medium containing different concentrations of drugs was added to continue culturing until the cell cytopathic effect of the virus control group was about 75%. CCK-8 was added to incubate in the dark for 1-4 hours, and the OD was measured. 450nm The half effective concentration (EC 50 ).

[0124] Experimental results:

[0125] In vitro toxicity results: Compound I, mabaloxavir, baloxavir, T-3 compound and T-4 compound all had certain toxic effects on MDCK cells. 50 The concentrations of the active ingredients in the formula I were 17.36 μM, 11.61 μM, 10.45 μM, 9.21 μM and 12.30 μM, respectively, indicating that the compound of formula I has the best safety for normal cells.

[0126] In vitro antiviral results: The compound of formula I has a good protective effect on cell damage infected by influenza virus at a concentration of 250nM, and can inhibit the production of viral cytopathic effects. Its EC 50 The values ​​were 5.02 nM and 8.15 nM, respectively.

[0127] EC of the compound of formula I, mabaloxavir, baloxavir, T-3 compound and T-4 compound against influenza A virus subtype H3N2 strain (A / California / 2 / 2014) 50The values ​​were 5.02nM, 13.42nM, 1.31nM, 8.54nM and 7.21nM, respectively, indicating that the order of their anti-influenza A virus activity is: mabaloxavir < T-3 compound < T-4 compound < compound of formula I < baloxavir; the EC values ​​of compound of formula I, mabaloxavir, baloxavir, T-3 compound and T-4 compound for influenza B virus strain (B / Florida / 78 / 2015) 50 The values ​​were 8.15nM, 15.39nM, 2.06nM, 10.41nM and 11.98nM, respectively, indicating that the order of anti-influenza B virus effect was: mabaloxavir < T-4 compound < T-3 compound < compound of formula I < baloxavir.

[0128] Example B In vivo anti-influenza virus pharmacodynamics study

[0129] In this example, BALB / c mice were infected with H3N2 influenza A virus and IBV influenza B virus, respectively, by intranasal infection to establish influenza A and B virus infection models. After infection, the mice were orally gavaged with the compound of Formula I, and changes in the lung index and lung tissue viral load of the mice were observed. Oseltamivir phosphate granules, mabaloxavir, T-3 compound, and T-4 compound were set as positive control drugs to evaluate the anti-influenza virus efficacy of the compound of Formula I in vivo.

[0130] (1) In vivo pharmacodynamic study of the compound of formula I against H3N2 influenza A virus

[0131] Two hundred and fifty SPF-qualified BALB / c mice, weighing 11.9-15.1 g, were randomly divided into seven groups based on sex and weight: a normal control group, a model control group, an oseltamivir phosphate granule group (6 mg / kg), a mabaloxavir group (6 mg / kg), a T-3 compound group (6 mg / kg), a T-4 compound group (6 mg / kg), and a compound of Formula I group (6 mg / kg). The normal control group, oseltamivir phosphate granule group, mabaloxavir group, T-3 compound group (6 mg / kg), and T-4 compound group consisted of 30 animals each, while the model control group and the compound of Formula I group each consisted of 50 animals. Two hours before the first dose, mice in each group were lightly anesthetized with ether. All mice, except the normal control group, received intranasal instillation of 100 μL of H3N2 influenza A virus stock solution (virus titer 6 log²). The normal control group received an equal volume of phosphate buffer. Each group of mice was orally gavaged with a drug solution of corresponding concentration at 20 mL / kg, once a day for 5 consecutive days. The normal control group and the model control group were orally gavaged with an equal volume of 0.5% MC (0.5% methylcellulose). Each group of mice was weighed every day, and 10 mice, half male and half female, were randomly selected 24h and 48h after administration, and euthanized by cervical dislocation. The lungs were dissected and weighed, and the lung index was calculated. The real-time fluorescence quantitative PCR method was used to detect the influenza A virus load in the mouse lung tissue. 10 mice were killed in the model control group and the compound of formula I dosage group 12h, 24h and 48h, 72h, and 5d after administration, and the left lung was taken for H3N2 influenza A virus load investigation. The results are shown in Table 1 and Table 2, wherein Table 1 shows the effect of the compound of formula I on the lung index of mice infected with influenza A virus ( n=10); Table 2 shows the effect of the compound of formula I on the viral load in the lung tissue of mice infected with H3N2 influenza A virus ( n=10).

[0132] Table 1

[0133] Note: Compared with the normal control group ++ P≤0.01; compared with the model control group × P≤0.05, ×× P≤0.01.

[0134] Table 2

[0135] Note: Compared with the normal control group ++ P≤0.01; compared with the model control group × P≤0.05, ×× P≤0.01.

[0136] These results demonstrate that the compound of Formula I can inhibit the increase in lung index in mice infected with influenza A virus and significantly inhibit the replication of influenza A virus in the lungs of mice. This suggests that the compound of Formula I has significant in vivo anti-influenza A virus efficacy. Compared to the control compound at equivalent doses, the compound of Formula I exhibits superior in vivo anti-influenza A virus efficacy.

[0137] (2) In vivo pharmacodynamic study of the compound of formula I against influenza B virus

[0138] Two hundred and ten SPF-qualified BALB / c mice weighing 13.0-15.4 g (half male and half female) were randomly divided into seven groups based on sex and weight: a normal control group, a model control group, an oseltamivir phosphate granule group (6 mg / kg), a mabaloxavir group (6 mg / kg), a T-3 compound group (6 mg / kg), a T-4 compound group (6 mg / kg), and a compound of Formula I group (6 mg / kg), with 30 mice per group. Two hours before the first dose, mice in each group were lightly anesthetized with ether. All mice, except the normal control group, received intranasal instillation of 100 μL of IBV influenza B virus stock solution (virus titer 8 log2) with an equal volume of phosphate buffer. Each group received oral gavage of the corresponding drug concentration at 20 mL / kg once daily for five consecutive days. The normal and model control groups received an equal volume of 0.5% MC (0.5% methylcellulose). The mice in each group were weighed every day. Ten mice, half male and half female, were randomly selected 24 hours and 48 hours after administration, and euthanized by cervical dislocation. The lungs were dissected and weighed, and the lung index was calculated. The influenza B virus load in the lung tissue of the mice was detected by relative fluorescence quantitative PCR. The results are shown in Tables 3 and 4. Table 3 shows the effect of the compound of formula I on the lung index of mice infected with influenza B virus IBV ( n=10); Table 4 shows the effect of the compound of formula I on the viral load in the lung tissue of mice infected with IBV influenza B virus ( n=10).

[0139] Table 3

[0140] Note: Compared with the normal control group ++ P≤0.01; compared with the model control group × P≤0.05, ×× P≤0.01.

[0141] Table 4

[0142] Note: Compared with the normal control group ++ P≤0.01; compared with the model control group × P≤0.05, ××P≤0.01.

[0143] These results demonstrate that the compound of Formula I can inhibit the increase in lung index in mice infected with IBV influenza B virus and significantly inhibit IBV influenza B virus replication in the lungs of mice. This suggests that the compound of Formula I has significant in vivo anti-influenza B virus efficacy. Compared to the control compound at equivalent doses, the compound of Formula I exhibits superior in vivo anti-influenza B virus efficacy.

[0144] Example C Pharmacokinetic Experiment

[0145] The pharmacokinetic characteristics of methylcellulose (MC) suspension of compound I in rats were investigated by oral administration.

[0146] Baloxavir concentrations were determined using a validated LC-MS / MS method. Plasma samples were precipitated with acetonitrile, and the supernatant was sampled for analysis. A Waters XBridge C8 2.5 μm, 2.1 × 50 mm column was used. Gradient elution was performed using a mobile phase of 0.1% formic acid in water and acetonitrile (containing 0.1% formic acid) at a flow rate of 0.60 mL / min. Electrospray ionization (ESI) was used for monitoring in positive ion mode using multiple reaction monitoring (MRM). The linear range of baloxavir is 0.1000-100.0 ng / mL, and the lower limit of quantification is 0.1000 ng / mL; the linear range of mabaloxavir is 0.1000-5.000 ng / mL, and the lower limit of quantification is 0.1000 ng / mL; the linear range of the compound of formula I is 0.1000-5.000 ng / mL, and the lower limit of quantification is 0.1000 ng / mL, the linear range of the T-3 compound is 0.1000-5.000 ng / mL, and the lower limit of quantification is 0.1000 ng / mL, and the linear range of the T-4 compound is 0.1000-5.000 ng / mL, and the lower limit of quantification is 0.1000 ng / mL.

[0147] This experiment uses the marketed drug Mabaloxavir and similar compounds T-3 and T-4 as references to investigate the differences in the pharmacokinetic characteristics of single-dose compounds of Formula I and the above-mentioned compounds. The Mabaloxavir dose group was designed as follows: medium dose (0.9 mg / kg, calculated as baloxavir), the T-3 and T-4 compound dose groups were designed as follows: medium dose (0.9 mg / kg), and the Formula I compound dose group was designed as follows: medium dose (0.9 mg / kg). Before administration (0h), and 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 12h, and 24h after administration, about 0.2mL of blood was collected from the orbits, and the plasma was separated by centrifugation at 1700g for 10min. The blood drug concentration was determined by LC-MS / MS method. The measured concentration value was lower than 80% of the lower limit of quantification of the analyte, which was considered as not detected (counted as zero) or lower than the lower limit of quantification (counted as ND).max The value before the peak was calculated as zero, and the value after the peak was calculated as ND. Phoenix winnonlin 8.0 software was used to calculate the pharmacokinetic parameters.

[0148] Results of the main pharmacokinetic parameters test: After SD rats were orally gavaged with different doses of the suspension of the compound of formula I, the main pharmacokinetic parameters were shown in Table 5 below.

[0149] Table 5

[0150] The test results show that the compound of the present application shows better pharmacokinetic properties than mabaloxavir, T-3 compound and T-4 compound.

Claims

1. A compound, which is a compound represented by formula X, or a pharmaceutically acceptable salt thereof, Wherein R is selected from H, Fmoc or 2. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein R is 3. The pharmaceutical composition according to claim 2, in, The pharmaceutical composition further comprises one or more additional therapeutic agents.

4. The pharmaceutical composition according to claim 3, in, The other therapeutic agent is selected from an anti-influenza virus agent or a vaccine.

5. The pharmaceutical composition according to claim 4, in, The other therapeutic agent is selected from at least one of oseltamivir, zanamivir, peramivir, laninamivir, favipiravir, arbidol hydrochloride, amantadine, methylamantadine, ribavirin, stavorine, ingavirine, baloxavir and vaccines.

6. Use of the compound according to claim 1 or the pharmaceutical composition according to any one of claims 2 to 5 in the preparation of a medicament for preventing, treating, curing or alleviating influenza virus infection in patients, wherein R is 7. A method for preparing a compound of formula X, wherein R is Fmoc, comprising the steps of: Step 1: Compound IV, compound V, an acid-binding agent, and a reaction solvent undergo an esterification reaction at a certain temperature to generate a compound of formula VI; and Step 2: Compound III, compound VI, a base, a catalyst, and a reaction solvent undergo a substitution reaction at a certain temperature to generate a compound of formula VII; 8. A method for preparing a compound of formula X, wherein R is H, comprising subjecting compound VII, a base, and a reaction solvent to a deprotection reaction at a certain temperature to produce a compound of formula VIII; 9. A method for preparing a compound of formula X, wherein R is The method comprises the following steps: a compound VIII, a compound IX, a condensing agent, a catalyst, and a reaction solvent undergo a condensation reaction at a certain temperature to generate a compound of formula I; 10. A method for preparing a compound of formula X, wherein R is It includes the following steps: Step 1: Compound II, 9-fluorenylmethyl chloroformate, sodium bicarbonate and 1,4-dioxane are subjected to a condensation reaction at 0-40° C. and then subjected to a hydrolysis reaction with lithium chloride and N-methylpyrrolidone at 60-100° C. to generate a compound of formula III; Step 2: Compound IV, compound V, pyridine and dichloromethane undergo esterification reaction at -10-40°C to produce compound VI; Compound III, compound VI, potassium carbonate, potassium iodide and N,N-dimethylformamide undergo substitution reaction at 40-70°C to produce compound VII; Step 3: Compound VII, hexahydropyridine and dichloromethane undergo a deprotection reaction at 10-40° C. to generate a compound of formula VIII; as well as Step 4: Compound VIII, compound IX, 1-propylphosphoric acid cyclic anhydride, methanesulfonic acid, ethyl acetate and cyclohexane are subjected to condensation reaction at 60-80° C. to produce a compound of formula I;

Citation Information

Patent Citations

  • Polycyclic pyridone compound as well as pharmaceutical composition and application thereof

    CN109503625A

  • Substituted polycyclic pyridone compound and prodrug thereof

    CN110317211A

  • Deuterated dihydrodibenzothiazepine compound and pharmaceutical composition containing same

    CN112409379A

  • Compound as well as preparation method, pharmaceutical composition and application thereof

    CN116284048A